Noticias Farmacéuticas

Licensing agreements signed for ustekinumab biosimilars

INICIO/Noticias Farmacéuticas | Posted 17/09/2021

Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals.

Oncogen–BrightGene partnership

INICIO/Noticias Farmacéuticas | Posted 10/09/2021

In June 2021, Malaysian oncology generics company, Oncogen, and China’s BrightGene Bio-Medical Technology announced that they are partnering to develop, manufacture, market and distribute generic drug products for the US market. 

Menagen–CKD Middle Eastern partnership

INICIO/Noticias Farmacéuticas | Posted 03/09/2021

Omani company, Menagen Pharmaceutical Industries and Korean company, Chong Kun Dang Pharmaceutical Corp (CKD), have formed a strategic partnership to provide biosimilars to countries in the Middle East.

Teva signs deal with Bioeq for ranibizumab biosimilar FYB201

INICIO/Noticias Farmacéuticas | Posted 30/07/2021

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Swiss biotechnology company Bioeq AG announced on 28 June 2021 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s candidate ranibizumab biosimilar (FYB201) in Europe, Canada, Israel and New Zealand.

Organon se lanza como nueva empresa global de salud de la mujer y nombra líderes en América Latina

INICIO/Noticias Farmacéuticas | Posted 23/07/2021

Organon celebró su lanzamiento como empresa global de salud femenina el 3 de junio de 2021 con empleados y mujeres de todo el mundo, mientras el equipo de liderazgo ejecutivo de Organon toca el timbre de apertura en la Bolsa de Nueva York.

Prestige-Cytiva partnership and new Korean R & D facility

INICIO/Noticias Farmacéuticas | Posted 09/07/2021

Singapore-based Prestige BioPharma, which specializes in the development of antibody therapeutics, is to build a new research and development (R & D) facility in the Republic of Korea and has entered a strategic partnership with Cytiva.

Theramex to market Prolia biosimilar in Europe and Australia

INICIO/Noticias Farmacéuticas | Posted 25/06/2021

UK-based pharmaceutical company Theramex UK Ltd, which focuses on women’s health, has announced an agreement with India’s Enzene Biosciences Limited for the registration and commercialisation of a Prolia (denosumab) biosimilar in Europe and Australia.

AbbVie antitrust investigation and Sandoz biosimilar delay

INICIO/Noticias Farmacéuticas | Posted 04/06/2021

In May 2021, following the release of a report, it was announced that AbbVie is likely to be subject to an antitrust investigation due to claims it has delayed market entry of biosimilars of Humira (adalimumab). Alvotech also raised a complaint against AbbVie after being sued over their Humira biosimilar application. In addition, the US Supreme Court denied Sandoz the ability to release its Enbrel (etanercept) biosimilar.

Merck partners with Indian drugmakers to increase access to COVID-19 drug

INICIO/Noticias Farmacéuticas | Posted 21/05/2021

On 27 April 2021, Merck & Co Inc (also known as MSD Pharmaceuticals) announced that it had partnered with five Indian generic drug manufacturers to expand production and access to its experimental COVID-19 drug. 

Bevacizumab and insulin aspart non-originator biologicals to be sold in Russia

INICIO/Noticias Farmacéuticas | Posted 14/05/2021

Singapore-based Prestige Biopharma (Prestige) has formed an agreement with Russian company Pharmapark to commercialize Prestige’s bevacizumab non-originator biological in Russia. Russian company Geropharm has also launched an insulin aspart non-originator biological on the market in the country.